Condition: Barrett Esophagus · Dysplasia · Sponsor: University Hospital, Angers
Barrett Esophagus is a common pathology, with an estimated prevalence of 1.6% at risk of progression to precancerous mucosa (low to high grade dysplasia). The incidence of adenocarcinoma on BE is 0.5% per year. In the event of dysplasia or cancer in situ, it is currently recommended at international and particularly European level to eradicate BE. The treatment techniques used to date carry out thermal destruction of the BE, in particular by radiofrequency. Eradication of dysplasia is achieved in 81% to 100% and disappearance of BE in 73% to 87% of cases. It requires an average of 3 destruction sessions. RF does not allow histological analysis after destruction of BE, but the risk of progression to neoplasia is estimated at 7.8/1000 persons per year. This risk could be due to the presence of glands buried in the esophageal mucosa. Indeed, these glands are not destroyed by thermal ablation methods, and remain invisible during endoscopic controls. A new treatment technique using the Endorotor® system allows mechanical resection of the entire mucosa in one session of treatment. In addition, the cost of these thermal destruction techniques currently limits their wider diffusion. It is therefore legitimate to propose a less expensive and probably more effective alternative technique.
This description comes directly from the study's public registry record.
Elodie CESBRON-METIVIER, Ph.D. · +33241353148 · elcesbronmetivier@chu-angers.fr
DRCI CHU Angers · +33241356329 · drci-promotion-interne@chu-angers.fr
Always discuss trial participation with your own doctor first.
| University Hospital of Besançon | Besançon, France | Recruiting |
| University Hospital of Brest | Brest, France | Not Yet Recruiting |
| University Hospital of Tours | Chambray-lès-Tours, France | Recruiting |
| University Hospital of Dijon | Dijon, France | Recruiting |
| University Hospital of Lille | Lille, France | Recruiting |
| University Hospital of Limoges | Limoges, France | Recruiting |
| Edouard Herriot Hospital | Lyon, France | Recruiting |
| University Hospital of Montpellier | Montpellier, France | Recruiting |
| University Hospital of Nancy | Nancy, France | Recruiting |
| University Hospital of Nantes | Nantes, France | Recruiting |
| University Hospital of Nice | Nice, France | Not Yet Recruiting |
| Cochin Hospital | Paris, France | Active Not Recruiting |
+ 5 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04867590